Andreas Busch's departure as Chief Innovation Officer of Absci Corp was reported, effective March 31, 2026; the filing names no successor. As of November 14, 2026, Absci Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 6, 2026, naming 1 departure (Form 8-K, March 6, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Absci Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Absci Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-06. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Absci Corp files it.
Also on the record for Absci Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 6.95% of the class | 5%+ stakes | Source |
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.8% of the class | 5%+ stakes | Source |
| April 14, 2026 | Stake report, Schedule 13D/A, by Redmile Group, LLC | 4.9% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13D/A, by Redmile Group, LLC | 5.4% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G, by The Vanguard Group | 5.26% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Sean McClain | 7.2% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.87% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G, by The Vanguard Group | 5.05% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Absci Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Absci Corp and the records around it.
Absci Corp elsewhere on the record
Companies that share a holder
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- ARK Investment Management LLC also filed stake reports on 23 other companies: Beam Therapeutics Inc. (Nov 2026), CERUS CORP (Nov 2026), CRISPR Therapeutics AG (Nov 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Absci Corp
Get an email when Absci Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Absci Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Absci Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Absci Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-06 | Out | Chief Innovation Officer | 2026-03-31 | 8-K, 2026-03-06 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Andreas Busch, Chief Innovation Officer (filed 2026-03-06):
Dr. Busch's resignation was not the result of any disagreement with the operations, policies or practices of the Company.
Who leads Absci Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Innovation Officer: Andreas Busch, departure reported, effective 2026-03-31 (filed 2026-03-06). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Absci Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Innovation Officer at Absci Corp, with the record behind each one.
Find candidates like Chief Innovation Officer at Absci CorpEvery change, in the filing's words
Departing: Andreas Busch, Chief Innovation Officer, effective 2026-03-31
D eparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 3, 2026 (the " Retirement Date "), the Company announced that Andreas Busch, Ph.D., the Company's Chief Innovation Officer, and an employee of the Company's wholly-owned subsidiary Absci GmbH, has informed the Company of his decision to retire, effective March 31, 2026.
- Dr. Busch will continue to provide services to the Company as a scientific advisor beginning on April 3, 2026 (the "Advisory Effective Date").
- In connection with Dr. Busch's continued services to the Company as a scientific advisor, the Company entered into an Advisor Agreement with Dr. Busch (the "Advisor Agreement"), pursuant to which Dr. Busch will provide the Company with advisory services for a term of two years beginning on the Advisory Effective Date (the "Advisory Term") (unless terminated earlier pursuant to the terms of the Advisor Agreement).
- Dr. Busch will receive cash compensation in the form of an annual retainer in the amount of U.S. $25,500, payable quarterly in arrears and prorated for any partial calendar quarter of services provided under the Advisor Agreement unless otherwise agreed by the parties.
- Dr. Busch will also be granted stock options for 22,800 shares and 5,800 restricted stock units under the Company's 2021 Stock Option and Incentive Plan (the "Plan") for services under the Advisor agreement.
- All of the stock options held by Dr. Busch as of the Retirement Date that remained unvested as of such date will terminate and will no longer be exercisable.
- On March 6, 2026, each of the Company's current directors and officers entered into an A&R Form Indemnification Agreement with the Company.
Tools for this story
Each opens in a new tab, filled in for Absci Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
